Telix shares soar after reiterating 2025 revenue guidance
Make us a preferred source
Make us a preferred source on Google
More news: Shares in Telix Pharmaceuticals surged after the company reiterated its 2025 revenue guidance amid increased investment and business expansion.
At 2:57pm AEST Telix’s share price had lifted 7.8% to $18.24.
As previously flagged, Telix revenue had increased by 63% year on year for the first half of 2025.
What they said: Telix managing director and group CEO Christian Behrenbruch said the company “continues to deliver strong revenue growth while building a foundation for the future”.
“The first half of 2025 was a period of rapid transformation as we expanded our global manufacturing operations, invested in launching new products in new markets, and accelerated the development of our therapeutic pipeline.
“These investments have positioned Telix for sustainable, long-term growth, while our diversified business provides multiple drivers of success.”
Telix Pharmaceuticals posts $4m loss as it expands operations
The news: Telix Pharmaceuticals has swung to a USD2.29 million ($3.56 million) loss after tax for the first half of 2025, down from the USD19.6 million profit generated in the first half of 2024.
The company said that it has expanded operations, supported the launch of new products and increased R&D investment.
The numbers: The first-half loss is below the market consensus estimate for a profit of USD38.1 million, according to Visible Alpha.
First-half revenue came in at USD390.4 million, up 63% on the previous comparable period, remaining on track to meet the guidance range of USD770 million and USD800 million. It is also higher than the expected USD382.8 million. Adjusted EBITDA lifted 24% year-on-year to $104.6 million.
Operational expenditure came in at USD395.2 million, up from USD216.7 million in FY24.
Telix confirmed that it is on track to meet FY2025 revenue guidance of between USD770 million and USD800 million driven by revenue from sales of prostate cancer treatment Illuccix and 11 months of revenue contribution from recently acquired US radiopharmacy network RLS.
The context: Telix increased its research and development expenditure by 47% year on year to $81.6 million, with a "focus on late-stage assets in the therapeutics and precision medicine pipeline".
Telix also faced increased amortisation cost of USD9.5 million following its agreement to acquire RLS in September 2024. Non-cash finance costs of USD12.4 million were also associated with convertible bonds issued in July 2024.
The source: ASX
